TORONTO, June 13 /CNW/ - Lorus Therapeutics Inc. (TSX: LOR, AMEX: LRP)
("Lorus" or the "Corporation"), a biopharmaceutical company specializing in
the research and development of pharmaceutical products and technologies for
the management of cancer, today announced that it has filed a preliminary
short form prospectus in each of the provinces of Canada in connection with a
distribution to its shareholders of rights exercisable for units of the
Corporation (the "Rights Offering").
